Integrating Interleukin-6 into depression diagnosis and treatment

Neurobiology of Stress

Volumn 4, Issue , 2016, Pages 15-22

  Hodes, Georgia E ^a   Ménard, Caroline ^a   Russo, Scott J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FLUOXETINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MACROPHAGE INHIBITING FACTOR; SILTUXIMAB; SIRUKUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANXIETY; CLINICAL TRIAL (TOPIC); COPING BEHAVIOR; CYTOKINE RELEASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE PREDISPOSITION; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; LEARNED HELPLESSNESS; MOOD DISORDER; NERVE CELL PLASTICITY; NONHUMAN; NUCLEUS ACCUMBENS; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SOCIAL INTERACTION; STRESS; SYNAPTIC INHIBITION; TREATMENT RESPONSE;

EID: 84962037349     PISSN: None     EISSN: 23522895     Source Type: Journal    
DOI: 10.1016/j.ynstr.2016.03.003     Document Type: Review

References (95)

1. Audet, M.C., Anisman, H., Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses. Front. Cell Neurosci., 7, 2013, 68.
2. Bluthe, R.M., Dantzer, R., Kelley, K.W., Effects of interleukin-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Res. 573 (1992), 318–320.
3. Bob, P., Raboch, J., Maes, M., Susta, M., Pavlat, J., Jasova, D., Vevera, J., Uhrova, J., Benakova, H., Zima, T., Depression, traumatic stress and interleukin-6. J. Affect Disord. 120 (2010), 231–234.
4. Boufidou, F., Lambrinoudaki, I., Argeitis, J., Zervas, I.M., Pliatsika, P., Leonardou, A.A., Petropoulos, G., Hasiakos, D., Papadias, K., Nikolaou, C., CSF and plasma cytokines at delivery and postpartum mood disturbances. J. Affect Disord. 115 (2009), 287–292.
5. Brietzke, E., Scheinberg, M., Lafer, B., Therapeutic potential of interleukin-6 antagonism in bipolar disorder. Med. Hypotheses 76 (2011), 21–23.
6. Cattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K.J., Craig, I.W., Anacker, C., Zunsztain, P.A., McGuffin, P., Pariante, C.M., Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets'. Neuropsychopharmacology 38 (2013), 377–385.
7. Chourbaji, S., Urani, A., Inta, I., Sanchis-Segura, C., Brandwein, C., Zink, M., Schwaninger, M., Gass, P., IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol. Dis. 23 (2006), 587–594.
8. Christoffel, D.J., Golden, S.A., Russo, S.J., Structural and synaptic plasticity in stress-related disorders. Rev. Neurosci. 22 (2011), 535–549.
9. Christoffel, D.J., Golden, S.A., Heshmati, M., Graham, A., Birnbaum, S., Neve, R.L., Hodes, G.E., Russo, S.J., Effects of inhibitor of kappaB kinase activity in the nucleus accumbens on emotional behavior. Neuropsychopharmacology 37 (2012), 2615–2623.
10. Christoffel, D.J., Golden, S.A., Dumitriu, D., Robison, A.J., Janssen, W.G., Ahn, H.F., Krishnan, V., Reyes, C.M., Han, M.H., Ables, J.L., Eisch, A.J., Dietz, D.M., Ferguson, D., Neve, R.L., Greengard, P., Kim, Y., Morrison, J.H., Russo, S.J., IkappaB kinase regulates social defeat stress-induced synaptic and behavioral plasticity. J. Neurosci. 31 (2011), 314–321.
11. Cole, S.W., Arevalo, J.M., Takahashi, R., Sloan, E.K., Lutgendorf, S.K., Sood, A.K., Sheridan, J.F., Seeman, T.E., Computational identification of gene-social environment interaction at the human IL6 locus. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 5681–5686.
12. Coppack, S.W., Pro-inflammatory cytokines and adipose tissue. Proc. Nutr. Soc. 60 (2001), 349–356.
13. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9 (2008), 46–56.
14. De Bosscher, K., Vanden Berghe, W., Vermeulen, L., Plaisance, S., Boone, E., Haegeman, G., Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 3919–3924.
15. De Kock, M., Loix, S., Lavand'homme, P., Ketamine and peripheral inflammation. CNS Neurosci. Ther. 19 (2013), 403–410.
16. Dendorfer, U., Oettgen, P., Libermann, T.A., Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol. Cell Biol. 14 (1994), 4443–4454.
17. Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctot, K.L., A meta-analysis of cytokines in major depression. Biol. Psychiatry 67 (2010), 446–457.
18. Eller, T., Vasar, V., Shlik, J., Maron, E., Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (2008), 445–450.
19. Endrighi, R., Hamer, M., Steptoe, A., Post-menopausal women exhibit greater interleukin-6 responses to mental stress than older men. Ann. Behav. Med., 2016, 10.1007/s12160-016-9783-y [Epub ahead of print].
20. Farooq, R.K., Isingrini, E., Tanti, A., Le Guisquet, A.M., Arlicot, N., Minier, F., Leman, S., Chalon, S., Belzung, C., Camus, V., Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation?. Behav. Brain Res. 231 (2012), 130–137.
21. Garcia-Oscos, F., Pena, D., Housini, M., Cheng, D., Lopez, D., Borland, M.S., Salgado-Delgado, R., Salgado, H., D'Mello, S., Kilgard, M.P., Rose-John, S., Atzori, M., Vagal nerve stimulation blocks interleukin 6-dependent synaptic hyperexcitability induced by lipopolysaccharide-induced acute stress in the rodent prefrontal cortex. Brain Behav. Immun. 43 (2015), 149–158.
22. Golden, S.A., Covington, H.E. 3rd, Berton, O., Russo, S.J., A standardized protocol for repeated social defeat stress in mice. Nat. Protoc. 6 (2011), 1183–1191.
23. Golden, S.A., Christoffel, D.J., Heshmati, M., Hodes, G.E., Magida, J., Davis, K., Cahill, M.E., Dias, C., Ribeiro, E., Ables, J.L., Kennedy, P.J., Robison, A.J., Gonzalez-Maeso, J., Neve, R.L., Turecki, G., Ghose, S., Tamminga, C.A., Russo, S.J., Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression. Nat. Med. 19 (2013), 337–344.
24. Haapakoski, R., Mathieu, J., Ebmeier, K.P., Alenius, H., Kivimaki, M., Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav. Immun. 49 (2015), 206–215.
25. Hannestad, J., DellaGioia, N., Bloch, M., The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36 (2011), 2452–2459.
26. Harley, J., Luty, S., Carter, J., Mulder, R., Joyce, P., Elevated C-reactive protein in depression: a predictor of good long-term outcome with antidepressants and poor outcome with psychotherapy. J. Psychopharmacol. 24 (2010), 625–626.
27. Hoang, H., Laursen, B., Stenager, E.N., Stenager, E., Psychiatric co-morbidity in multiple sclerosis: the risk of depression and anxiety before and after MS diagnosis. Mult. Scler. 22:3 (2016 Mar), 347–353.
28. Hodes, G.E., Kana, V., Menard, C., Merad, M., Russo, S.J., Neuroimmune mechanisms of depression. Nat. Neurosci. 18 (2015), 1386–1393.
29. Hodes, G.E., et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 16136–16141.
30. Hsu, B., Wang, D., Sun, Y., Salvadore, G., Singh, J., Curran, M., Caers, I., Drevets, W., Wittenberg, G., Chen, G., SAT0182 improvement in measures of depressed mood and anhedonia, and fatigue, in a randomized, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 antibody, in patients with rheumatoid arthritis. Ann. Rheum. Dis., 74, 2015 720.723-721.
31. Jarskog, L.F., Xiao, H., Wilkie, M.B., Lauder, J.M., Gilmore, J.H., Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int. J. Dev. Neurosci. 15 (1997), 711–716.
32. Jazayeri, S., Keshavarz, S.A., Tehrani-Doost, M., Djalali, M., Hosseini, M., Amini, H., Chamari, M., Djazayery, A., Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res. 178 (2010), 112–115.
33. Joaquim, A.F., Appenzeller, S., Neuropsychiatric manifestations in rheumatoid arthritis. Autoimmun. Rev. 14 (2015), 1116–1122.
34. Kallaur, A.P., Lopes, J., Oliveira, S.R., Simao, A.N., Reiche, E.M., de Almeida, E.R., Morimoto, H.K., de Pereira, W.L., Alfieri, D.F., Borelli, S.D., Kaimen-Maciel, D.R., Maes, M., Immune-inflammatory and oxidative and nitrosative stress biomarkers of depression symptoms in subjects with multiple sclerosis: increased peripheral inflammation but less acute neuroinflammation. Mol. Neurobiol., 24 September 2015, 1–12, 10.1007/s12035-015-9443-4.
35. Kern, S., Skoog, I., Borjesson-Hanson, A., Blennow, K., Zetterberg, H., Ostling, S., Kern, J., Gudmundsson, P., Marlow, T., Rosengren, L., Waern, M., Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. Brain Behav. Immun. 41 (2014), 55–58.
36. Kessler, R.C., McGonagle, K.A., Swartz, M., Blazer, D.G., Nelson, C.B., Sex and depression in the national comorbidity survey. I: lifetime prevalence, chronicity and recurrence. J. Affect Disord. 29 (1993), 85–96.
37. Khandaker, G.M., Pearson, R.M., Zammit, S., Lewis, G., Jones, P.B., Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 71 (2014), 1121–1128.
38. Krishnan, V., Nestler, E.J., The molecular neurobiology of depression. Nature 455 (2008), 894–902.
39. Krishnan, V., et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131 (2007), 391–404.
40. Kubera, M., Kenis, G., Bosmans, E., Kajta, M., Basta-Kaim, A., Scharpe, S., Budziszewska, B., Maes, M., Stimulatory effect of antidepressants on the production of IL-6. Int. Immunopharmacol. 4 (2004), 185–192.
41. Lanquillon, S., Krieg, J.C., Bening-Abu-Shach, U., Vedder, H., Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22 (2000), 370–379.
42. Li, B., Hou, Y., Zhu, M., Bao, H., Nie, J., Zhang, G.Y., Shan, L., Yao, Y., Du, K., Yang, H., Li, M., Zheng, B., Xu, X., Xiao, C., Du, J., 3'-Deoxyadenosine (Cordycepin) produces a rapid and robust antidepressant effect via enhancing prefrontal AMPA receptor signaling pathway. Int. J. Neuropsychopharmacol., 2015 Oct 6, 10.1093/ijnp/pyv112 pii: pyv112. [Epub ahead of print].
43. Li, X.Z., Bai, L.M., Yang, Y.P., Luo, W.F., Hu, W.D., Chen, J.P., Mao, C.J., Liu, C.F., Effects of IL-6 secreted from astrocytes on the survival of dopaminergic neurons in lipopolysaccharide-induced inflammation. Neurosci. Res. 65 (2009), 252–258.
44. Libermann, T.A., Baltimore, D., Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol. Cell Biol. 10 (1990), 2327–2334.
45. Lindqvist, D., Janelidze, S., Hagell, P., Erhardt, S., Samuelsson, M., Minthon, L., Hansson, O., Bjorkqvist, M., Traskman-Bendz, L., Brundin, L., Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol. Psychiatry 66 (2009), 287–292.
46. Lust, J.A., Donovan, K.A., Kline, M.P., Greipp, P.R., Kyle, R.A., Maihle, N.J., Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 4 (1992), 96–100.
47. Maes, M., Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 19 (1995), 11–38.
48. Maes, M., Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. 461 (1999), 25–46.
49. Maes, M., Meltzer, H.Y., Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., Desnyder, R., Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect Disord. 34 (1995), 301–309.
50. Maes, M., Van der Planken, M., Stevens, W.J., Peeters, D., DeClerck, L.S., Bridts, C.H., Schotte, C., Cosyns, P., Leukocytosis, monocytosis and neutrophilia: hallmarks of severe depression. J. Psychiatr. Res. 26 (1992), 125–134.
51. Marrie, R.A., Fisk, J.D., Tremlett, H., Wolfson, C., Warren, S., Tennakoon, A., Leung, S., Patten, S.B., Epidemiology CTit, impact of comorbidity on multiple S. Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology 85:22 (2015 Dec 1), 1972–1979, 10.1212/WNL.0000000000002174 Epub 2015 Oct 30.
52. Matcham, F., Norton, S., Scott, D.L., Steer, S., Hotopf, M., Symptoms of Depression and Anxiety Predict Treatment Response and Long-term Physical Health Outcomes in Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial. 2015, Rheumatology, Oxford.
53. McDonough, E., Ayearst, R., Eder, L., Chandran, V., Rosen, C.F., Thavaneswaran, A., Gladman, D.D., Depression and anxiety in psoriatic disease: prevalence and associated factors. J. Rheumatol. 41 (2014), 887–896.
54. Meagher, M.W., Johnson, R.R., Young, E.E., Vichaya, E.G., Lunt, S., Hardin, E.A., Connor, M.A., Welsh, C.J., Interleukin-6 as a mechanism for the adverse effects of social stress on acute Theiler's virus infection. Brain Behav. Immun. 21 (2007), 1083–1095.
55. Moieni, M., Irwin, M.R., Jevtic, I., Olmstead, R., Breen, E.C., Eisenberger, N.I., Sex differences in depressive and socioemotional responses to an inflammatory challenge: implications for sex differences in depression. Neuropsychopharmacology 40 (2015), 1709–1716.
56. Monje, F.J., Cabatic, M., Divisch, I., Kim, E.J., Herkner, K.R., Binder, B.R., Pollak, D.D., Constant darkness induces IL-6-dependent depression-like behavior through the NF-kappaB signaling pathway. J. Neurosci. 31 (2011), 9075–9083.
57. Mormede, C., Castanon, N., Medina, C., Moze, E., Lestage, J., Neveu, P.J., Dantzer, R., Chronic mild stress in mice decreases peripheral cytokine and increases central cytokine expression independently of IL-10 regulation of the cytokine network. Neuroimmunomodulation 10 (2002), 359–366.
58. Mullberg, J., Schooltink, H., Stoyan, T., Gunther, M., Graeve, L., Buse, G., Mackiewicz, A., Heinrich, P.C., Rose-John, S., The soluble interleukin-6 receptor is generated by shedding. Eur. J. Immunol. 23 (1993), 473–480.
59. Murakami, M., Hirano, T., The pathological and physiological roles of IL-6 amplifier activation. Int. J. Biol. Sci. 8 (2012), 1267–1280.
60. Mutlu, O., Gumuslu, E., Ulak, G., Celikyurt, I.K., Kokturk, S., Kir, H.M., Akar, F., Erden, F., Effects of fluoxetine, tianeptine and olanzapine on unpredictable chronic mild stress-induced depression-like behavior in mice. Life Sci. 91 (2012), 1252–1262.
61. O'Brien, S.M., Scully, P., Fitzgerald, P., Scott, L.V., Dinan, T.G., Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatr. Res. 41 (2007), 326–331.
62. O'Brien, S.M., Fitzgerald, P., Scully, P., Landers, A., Scott, L.V., Dinan, T.G., Impact of gender and menstrual cycle phase on plasma cytokine concentrations. Neuroimmunomodulation 14 (2007), 84–90.
63. Pan, Y., Zhang, W.Y., Xia, X., Kong, L.D., Effects of icariin on hypothalamic-pituitary-adrenal axis action and cytokine levels in stressed Sprague-Dawley rats. Biol. Pharm. Bull. 29 (2006), 2399–2403.
64. Pfau, M.L., Russo, S.J., Peripheral and central mechanisms of stress resilience. Neurobiol. Stress 1 (2015), 66–79.
65. Rabin, F., Bhuiyan, S.I., Islam, T., Haque, M.A., Islam, M.A., Psychiatric and psychological comorbidities in patients with psoriasis- a review. Mymensingh Med. J. 21 (2012), 780–786.
66. Ramirez, K., Shea, D.T., McKim, D.B., Reader, B.F., Sheridan, J.F., Imipramine attenuates neuroinflammatory signaling and reverses stress-induced social avoidance. Brain Behav. Immun. 46 (2015), 212–220.
67. Ray, A., Prefontaine, K.E., Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 752–756.
68. Reus, G.Z., Nacif, M.P., Abelaira, H.M., Tomaz, D.B., dos Santos, M.A., Carlessi, A.S., da Luz, J.R., Goncalves, R.C., Vuolo, F., Dal-Pizzol, F., Carvalho, A.F., Quevedo, J., Ketamine ameliorates depressive-like behaviors and immune alterations in adult rats following maternal deprivation. Neurosci. Lett. 584 (2015), 83–87.
69. Rossi, J.F., Lu, Z.Y., Jourdan, M., Klein, B., Interleukin-6 as a therapeutic target. Clin. Cancer Res. 21 (2015), 1248–1257.
70. Russo, S.J., Nestler, E.J., The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 14 (2013), 609–625.
71. Russo, S.J., Murrough, J.W., Han, M.H., Charney, D.S., Nestler, E.J., Neurobiology of resilience. Nat. Neurosci. 15 (2012), 1475–1484.
72. Ryan, S., McGuire, B., Psychological predictors of pain severity, pain interference, depression, and anxiety in rheumatoid arthritis patients with chronic pain. Br. J. Health Psychol., 2015 Nov 3, 10.1111/bjhp.12171 [Epub ahead of print].
73. Sasayama, D., Hattori, K., Wakabayashi, C., Teraishi, T., Hori, H., Ota, M., Yoshida, S., Arima, K., Higuchi, T., Amano, N., Kunugi, H., Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J. Psychiatr. Res. 47 (2013), 401–406.
74. Scheller, J., Chalaris, A., Schmidt-Arras, D., Rose-John, S., The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. biophys. acta 1813 (2011), 878–888.
75. Sluzewska, A., Rybakowski, J.K., Laciak, M., Mackiewicz, A., Sobieska, M., Wiktorowicz, K., Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. N. Y. Acad. Sci. 762 (1995), 474–476.
76. Smith, R.S., The macrophage theory of depression. Med. Hypotheses 35 (1991), 298–306.
77. Smolen, J.S., Weinblatt, M.E., Sheng, S., Zhuang, Y., Hsu, B., Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann. Rheum. Dis. 73 (2014), 1616–1625.
78. Song, C., Merali, Z., Anisman, H., Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment. Neuroscience 88 (1999), 823–836.
79. Spooren, A., Kolmus, K., Laureys, G., Clinckers, R., De Keyser, J., Haegeman, G., Gerlo, S., Interleukin-6, a mental cytokine. Brain Res. Rev. 67 (2011), 157–183.
80. Sukoff Rizzo, S.J., Neal, S.J., Hughes, Z.A., Beyna, M., Rosenzweig-Lipson, S., Moss, S.J., Brandon, N.J., Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl. Psychiatry, 2, 2012, e199.
81. Tanaka, T., Kishimoto, T., The biology and medical implications of interleukin-6. Cancer Immunol. Res. 2 (2014), 288–294.
82. Tianzhu, Z., Shihai, Y., Juan, D., Antidepressant-like effects of cordycepin in a mice model of chronic unpredictable mild stress. Evid. Based Complement. Altern. Med., 2014, 2014, 438506.
83. Tonelli, L.H., Holmes, A., Postolache, T.T., Intranasal immune challenge induces sex-dependent depressive-like behavior and cytokine expression in the brain. Neuropsychopharmacology 33 (2008), 1038–1048.
84. Tulner, D.M., Smith, O.R., Schins, A., de Jonge, P., Quere, M., Delanghe, J.R., Crijns, H.J., den Boer, J.A., Korf, J., Honig, A., Antidepressive effect of mirtazapine in post-myocardial infarction depression is associated with soluble TNF-R1 increase: data from the MIND-IT. Neuropsychobiology 63 (2011), 169–176.
85. Venkiteshwaran, A., Tocilizumab. MAbs 1 (2009), 432–438.
86. Virtanen, M., Shipley, M.J., Batty, G.D., Hamer, M., Allan, C.L., Lowe, G.D., Ebmeier, K.P., Akbaraly, T.N., Alenius, H., Haapakoski, R., Singh-Manoux, A., Kivimaki, M., Interleukin-6 as a predictor of symptom resolution in psychological distress: a cohort study. Psychol. Med., 2015, 1–8.
87. Vogelzangs, N., Duivis, H.E., Beekman, A.T., Kluft, C., Neuteboom, J., Hoogendijk, W., Smit, J.H., de Jonge, P., Penninx, B.W., Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl. Psychiatry, 2, 2012, e79.
88. Walker, A.J., Foley, B.M., Sutor, S.L., McGillivray, J.A., Frye, M.A., Tye, S.J., Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance. Behav. Brain Res. 293 (2015), 198–202.
89. Walker, J.R., Graff, L.A., Dutz, J.P., Bernstein, C.N., Psychiatric disorders in patients with immune-mediated inflammatory diseases: prevalence, association with disease activity, and overall patient well-being. J. Rheumatol. Suppl. 88 (2011), 31–35.
90. Williams, S.C., First IL-6-blocking drug nears approval for rare blood disorder. Nat. Med., 19, 2013, 1193.
91. Wolf, J., Rose-John, S., Garbers, C., Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 70 (2014), 11–20.
92. Wood, S.K., Wood, C.S., Lombard, C.M., Lee, C.S., Zhang, X.Y., Finnell, J.E., Valentino, R.J., Inflammatory factors mediate vulnerability to a social stress-induced depressive-like phenotype in passive coping rats. Biol. Psychiatry 78 (2015), 38–48.
93. Yang, C., Shirayama, Y., Zhang, J.C., Ren, Q., Hashimoto, K., Peripheral interleukin-6 promotes resilience versus susceptibility to inescapable electric stress. Acta Neuropsychiatr., 2015, 1–5.
94. Yirmiya, R., Endotoxin produces a depressive-like episode in rats. Brain Res. 711 (1996), 163–174.
95. Zhang, Y.H., Lin, J.X., Vilcek, J., Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence. Mol. Cell Biol. 10 (1990), 3818–3823.